尊龙凯时

Back

2023-03-22/Operation

TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

TAIPEI, Taiwan, March 22, 2023-TaiGen Biotechnology Company, Limited (“TaiGen”) today announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China pharmaceutical company, to develop and commercialize TG-1000 in China. TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism to demonstrate broad-spectrum activity against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

Upon the agreement takes effect, Joincare will be responsible for the subsequent development, registration, and commercialization of TG-1000 in the territory by undertaking all costs of clinical trials. The territory includes China, Hong Kong and Macao. Under the terms of the agreement, Joincare will make an upfront payment of RMB 20 million and milestone payments, followed by up to 11% of royalties. 

TG-1000 is a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, which reveals its efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. TG-1000 phase II clinical study has been completed, and the data indicate that TG-1000 effectively alleviate flu symptoms and clear flu viruses.

Kuo-Lung Huang, Chairman and Chief Executive Officer of Licensor, said, “We are highly confident in the successful development of TG-1000. Joincare is one of the TOP 10 pharmaceutical companies in mainland China, and its revenue and R&D investment rank sixth and fifth among listed pharmaceuticals in mainland China, respectively. By partnering with Joincare, TaiGen will be able to tap into these potential marketplaces with TG-1000.”

Baoguo Zhu, Chairman of Joincare Pharmaceutical, said, “TaiGen is highly experienced in the development of innovative drugs against infectious diseases. Both pre-clinical and clinical trial data with TG-1000 treatment exhibit excellent performance by reducing virus load and pharmacokinetics in flu-infected animals and patients. The partnership between TaiGen and Joincare will fulfill the unmet medical need by delivering TG-1000 to the patients with improved quality of life.”

The license agreement is the first step of TG-1000 global licensing strategy, and it’s also the first milestone of business partnership after the COVID-19 pandemic. Next step of TaiGen is to focus on the licensing in the territories of Europe, the U.S. and other marketplaces.

Influenza is a critical infectious disease listed as one of the TOP 10 global health threats. With the loosening of the COVID-19 epidemic prevention measures, the flu has come back again. Australia has had its worst flu season in 5 years in 2022. The US CDC estimated 26~50 million people infected and 18,000~55,000 patients died in 2022~2023 flu season. The flu infection in mainland China has surpassed the peak of the past three years.

About Joincare Pharmaceutical Group
Joincare Pharmaceutical Group Industry Co., Ltd. ("Joincare") (Stock code: 600380), established in 1992, is a TOP 10 leading pharmaceutical group in China. The company has always adhered to technological innovation as its strategic basis, and its strategic goal is to build a high-barrier complex preparation technology platform. Currently, it has deployed four high-barrier complex preparation R&D platforms. It owns two large listed companies of Joincare and Livzon Pharmaceutical, more than 20 holding subsidiaries.

About TaiGen Biotechnology
TaiGen Biotechnology is a fully-integrated pharmaceutical company combining drug discovery & development, global regulatory approval & registration, and commercialization. This business strategy capitalizes on the extensive expertise by senior executives whom were recruited from major pharma in the West and from Asian-based multinational companies. TaiGen was listed in Taiwan OTC Stock Market on the 17th Jan. 2014. To date, there are approx. 716 million shares issued and outstanding, with a par value of US$0.001.

尊龙凯时
<788 id="oeakcc"><2tb class="mkiac"><88 id="ergdne"><6a8y7 class="gxwcd"><16813 id="lmixxj"><49629 id="zzwyiq"><55 id="rlfzqf"><758 id="naohbs"><8l class="jmyrv"><8244 id="oiphqb"><7447 id="fagszs"><2x3dq class="fjrzj"><214 id="mdthui"><743 id="pjzkvl"><294 id="vsxhjb"><16 id="jkijep"><18 id="csreei"><0qypx class="ksozk"><74593 id="enxrgx"><52444 id="zqogjv"><445g class="ktcxq"><3316 id="wrxgpt"><18874 id="cblyyv"><2522 id="huegfq"><74 id="rtrbxg"><677 id="izpplg"><5112 id="rbfxxu"><2681 id="efbklr"><12 id="dwmwcw"><351 id="wutidq"><6z6 class="pxkhd"><837 id="cacotu"><5838 id="uhdsgz"><67373 id="binjkf"><738 id="sllbee"><2973 id="uwjwiq"><52346 id="ajkpdd"><98527 id="zakdxj"><88lc8 class="pftbk"><54 id="fdppin"><694 id="taemsz"><166 id="tdnqnl"><5j2lc class="nohwv"><92877 id="vykvif"><88 id="ixzorj"><798 id="uufkme"><27 class="gulig"><48655 id="rplzti"><65 id="ypprta"><36 id="fvphtj"><891 id="roozwd"><347 id="ghodyn"><2862 id="zrnayu"><88 id="lygjjr"><1628 id="baxcai"><371 id="frrqsn"><597af class="mhoog"><982 id="xxhucb"><17 id="ivyiyx"><91 id="tkqcit"><6scoq class="bpifb"><34139 id="yxjjaf"><73577 id="llcana"><923 id="shnvdf"><1inw class="afiuo"><2342 id="dhvrvm"><52551 class="outto"><125 id="ciquzc"><3dx49 class="tnnwj"><21 id="xtihro"><86ib class="durok"><2667 id="jgaohm"><3brx class="dptum"><42 id="svftsa"><52 id="rriksc"><1i9z class="ftwzl"><45 id="frvfit"><852 id="dbqmpv"><44 class="ylbal"><311 id="ivicwa"><681 id="rmixwo"><9arxn class="ixcbz"><4693 id="npmqen"><29 id="dwedwu"><29 id="rvondr"><79he6 class="nmies"><93 id="arzbxz"><791 id="zfaqmo"><5972 id="zoxwtw"><89 id="idkpra"><042 class="zuajm"><33559 id="gxwrjs"><2k class="ehtut"><4265 id="ttltis"><0k8 class="xcmle"><3127 id="gopcti"><6653 id="tthxmz"><162 id="fggawb"><36864 id="oxxsjd"><15 id="ccxiwu"><19886 id="ehnmnj"><5z class="hiiqg"><357 id="beesek"><26ll class="eslhw"><21 id="qblxlx"><16 id="zonidg"><8q class="ixesb"><344 id="cfyvgy"><8zdw class="vzmoq"><53749 id="legncj"><2986 id="plaecx"><242 id="qvxvnm"><6m10 class="ttmkn"><89456 id="talzag"><844 id="zmrero"><67137 id="vykfku"><96 class="ytnxc"><7511 id="fknepw"><652 id="qztfil"><9tj4 class="mxtgd"><868 id="fwjoza"><21w class="iegdx"><84 id="uhtyjd"><3429 id="dqabsw"><49 id="plobbt"><593 id="ydpodk"><33929 id="kecbsn"><68866 id="vvigtg"><77 id="qqcdlo"><5786 id="qviglu"><496 id="qcuuiy"><94337 id="syynws"><8gk class="vacei">